References
- DuttaRTrappBDRelapsing and progressive forms of multiple sclerosis: insights from pathologyCurr Opin Neurol201427327127824722325
- KapposLRadueEWO’ConnorPA placebo-controlled trial of oral fingolimod in relapsing multiple sclerosisN Engl J Med2010362538740120089952
- CohenJABarkhofFComiGOral fingolimod or intramuscular interferon for relapsing multiple sclerosisN Engl J Med2010362540241520089954
- BerkeleyMJFungi. Flora Novae-Zelandiae. Part II. Flowerless plantsHookerJDThe Botany of the Antarctic Voyage IILondon, EnglandLovell Reeve1855172210
- LloydCGIsaria sinclairii. Mycol Writings192371179
- PatersonRRCordyceps: traditional Chinese medicine and another fungal therapeutic biofactory?Phytochemistry20086971469149518343466
- FujitaTInoueKYamamotoSFungal metabolites. Part 11. A potent immunosuppressive activity found in Isaria sinclairii metaboliteJ Antibiot19944722082158150717
- AdachiKKoharaTNakaoNDesign, synthesis, and structure-activity relationships of 2-substituted-2-amino-1,3-propanediols. Discovery of a novel immunosuppressant, FTY720Bioorg Med Chem Lett199558853856
- Tedesco-SilvaHPescovitzMDCibrikDRandomized controlled trial of FTY720 versus MMF in de novo renal transplantationTransplantation200682121689169717198261
- SalvadoriMBuddeKCharpentierBFTY720 versus MMF with cyclosporine in de novo renal transplantation: a 1-year, randomized controlled trial in Europe and AustralasiaAm J Transplant20066122912292117061999
- WebbMThamCSLinFFSphingosine 1-phosphate receptor agonists attenuate relapsing-remitting experimental autoimmune encephalitis in SJL miceJ Neuroimmunol200415310812115265669
- KapposLAntelJComiGOral fingolimod (FTY720) for relapsing multiple sclerosisN Engl J Med20063551124114016971719
- Cleveland clinicCleveland clinic innovations Available from: http://innovations.clevelandclinic.org/Summit-(1)/Top-10-Innovations/Top-10-for-2011.aspx#.VeIITM65dLwAccessed September 24, 2015
- LandersPMS drug’s epic journey from folklore to labThe Wall Street Journal6222010 Available from: http://www.wsj.com/articles/SB10001424052748704256304575320714138159240Accessed September 25, 2015
- ChunJHartungHPMechanism of action of oral fingolimod (FTY720) in multiple sclerosisClin Neuropharmacol20103329110120061941
- BrinkmannVBillichABaumrukerTFingolimod (FTY720): discovery and development of an oral drug to treat multiple sclerosisNat Rev Drug Discov201091188389721031003
- DevonshireVHavrdovaERadueEWRelapse and disability outcomes in patients with multiple sclerosis treated with fingolimod: subgroup analyses of the double-blind, randomised, placebo-controlled FREEDOMS studyLancet Neurol201211542042822494956
- CohenJABarkhofFComiGFingolimod versus intramuscular interferon in patient subgroups from TRANSFORMSJ Neurol201326082023203223632946
- CalabresiPARadueEWGoodinDSafety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trialLancet Neurol201413654555624685276
- NovartisNovartis provides update on fingolimod Phase III trial in primary progressive MS (PPMS) Available from: https://www.novartis.com/news/media-releases/novartis-provides-update-fingolimod-phase-iii-trial-primary-progressive-ms-ppmsAccessed September 20, 2015
- KapposLO’ConnorPRadueEWLong-term effects of fingolimod in multiple sclerosis: the randomized FREEDOMS extension trialNeurology201584151582159125795646
- CohenJAKhatriBBarkhofFLong-term (up to 4.5 years) treatment with fingolimod in multiple sclerosis: results from the extension of the randomised TRANSFORMS studyJ Neurol Neurosurg Psychiatry Epub2015625
- MontalbanXComiGAntelJLong-term results from a phase 2 extension study of fingolimod at high and approved dose in relapsing multiple sclerosisJ Neurol Epub201594
- CentonzeDRossiSRinaldiFGalloPSevere relapses under fingolimod treatment prescribed after natalizumabNeurology2012792004200523035063
- RinaldiFSeppiDCalabreseMPeriniPGalloPSwitching therapy from natalizumab to fingolimod in relapsing-remitting multiple sclerosis: clinical and magnetic resonance imaging findingsMult Scler2012181640164323100526
- DaelmanLMaitrotAMaaroufAChaunuMPPapeixCTourbahASevere multiple sclerosis reactivation under fingolimod 3 months after natalizumab withdrawalMult Scler2012181647164922907938
- JanderSTurowskiBKieseierBCHartungHPEmerging tumefactive multiple sclerosis after switching therapy from natalizumab to fingolimodMult Scler2012181650165223100527
- SempereAPMartín-MedinaPBerenguer-RuizLSwitching from natalizumab to fingolimod: an observational studyActa Neurol Scand2013128e6e1023336398
- BaldiEGuareschiAVitettaFPrevious treatment influences fingolimod efficacy in relapsing-remitting multiple sclerosis: results from an observational studyCurr Med Res Opin20143091849185524831186
- HoepnerRHavlaJEienbrökerCPredictors for multiple sclerosis relapses after switching from natalizumab to fingolimodMult Scler201420131714172024842961
- BiancoAPatanellaAKNocitiVSecond-line therapy with fingolimod for relapsing-remitting multiple sclerosis in clinical practice: the effect of previous exposure to natalizumabEur Neurol2015731–2576525402749
- GajofattoABianchiMRDeottoLBenedettiMDAre natalizumab and fingolimod analogous second-line options for the treatment of relapsing-remitting multiple sclerosis? A clinical practice observational studyEur Neurol2014723–417318025226868
- CarruthersRLRotsteinDLHealyBCChitnisTWeinerHLBuckleGJAn observational comparison of natalizumab vs fingolimod using JCV serology to determine therapyMult Scler201420101381139024852928
- KalincikTHorakovaDSpelmanTSwitch to natalizumab versus fingolimod in active relapsing-remitting multiple sclerosisAnn Neurol201577342543525546031
- BrauneSLangMBergmannANTC Study GroupSecond line use of fingolimod is as effective as natalizumab in a German out-patient RRMS cohortJ Neurol20132602981298524008757
- LaroniABrogiDMilesiVAbateLUccelliAMancardiGEarly switch to fingolimod may decrease the risk of disease recurrence after natalizumab interruptionMult Scler2012191236123723184503
- HavlaJTackenbergBHellwigKFingolimod reduces recurrence of disease activity after natalizumab withdrawal in multiple sclerosisJ Neurol20132601382138723266894
- de SezeJOngagnaJCCollonguesNReduction of the washout time between natalizumab and fingolimodMult Scler2013199124823722322
- CohenMMaillartETourbahASwitching from natalizumab to fingolimod in multiple sclerosis: a French prospective studyJAMA Neurol201471443644124566807
- ComiGGoldRDahlkeFRelapses in patients treated with fingolimod after previous exposure to natalizumabMult Scler201521678679025257618
- IaffaldanoPLucisanoGPozzilliCFingolimod versus interferon beta/glatiramer acetate after natalizumab suspension in multiple sclerosisBrain2015138Pt 113275328626362907
- KapposLRadueEWComiGSwitching from natalizumab to fingolimod: a randomized, placebo-controlled study in RRMSNeurology2015851293926024899
- AlroughaniRAlmullaALamdhadeSThussuAMultiple sclerosis reactivation postfingolimod cessation: is it IRIS?BMJ Case Rep20142014 pii: bcr2014206314
- La MantiaLProneVMarazziMRErminioCProttiAMultiple sclerosis rebound after fingolimod discontinuation for lymphopeniaNeurol Sci20143591485148624756193
- GhezziARoccaMABaronciniDDisease reactivation after fingolimod discontinuation in two multiple sclerosis patientsJ Neurol2013260132732923161460
- SempereAPBerenguer-RuizLFeliu-ReyERebound of disease activity during pregnancy after withdrawal of fingolimodEur J Neurol2013208e109e11023829238
- PiscollaEHakikiBPastòLRazzoliniLPortaccioEAmatoMPRebound after fingolimod suspension in a pediatric-onset multiple sclerosis patientJ Neurol201326061675167723645219
- KapposLCohenJCollinsWFingolimod in relapsing multiple sclerosis: an integrated analysis of safety findingsMult Scler Relat Disord20143449450425877062
- DiMarcoJPO’ConnorPCohenJAFirst-dose effects of fingolimod: pooled safety data from three phase 3 studiesMult Scler Relat Disord20143562963826265275
- LaroniABrogiDMorraVBSafety of the first dose of fingolimod for multiple sclerosis: results of an open-label clinical trialBMC Neurol2014146524690227
- GoldRComiGPalaceJAssessment of cardiac safety during fingolimod treatment initiation in a real-world relapsing multiple sclerosis population: a phase 3b, open-label studyJ Neurol2014261226727624221641
- RamseierSPRothSCzaplinskiAA Swiss real world best practice experience in three different clinical settings of the 6 hour fingolimod first dose observation procedureBMC Pharmacol Toxicol201516725889400
- PaolicelliDManniADirenzoVLong-term cardiac safety and tolerability of fingolimod in multiple sclerosis: a postmarketing studyJ Clin Pharmacol201555101131113625903516
- ArvinAMWolinskyJSKapposLVaricella-zoster virus infections in patients treated with fingolimod: risk assessment and consensus recommendations for managementJAMA Neurol2015721313925419615
- JainNBhattiMTFingolimod-associated macular edema: incidence, detection, and managementNeurology201278967268022371414
- ZarbinMAJampolLMJagerRDOphthalmic evaluations in clinical studies of fingolimod (FTY720) in multiple sclerosisOphthalmology201312071432143923531349
- gilenyaworldwatch.com [homepage on the Internet] Available from: http://www.gilenyaworldwatch.com/English.htmlAccessed September 25, 2015
- US Food Drug AdministrationFDA Drug Safety Communication: revised recommendations for cardiovascular monitoring and use of multiple sclerosis drug Gilenya (fingolimod) Available from: http://www.fda.gov/Drugs/DrugSafety/ucm303192.htmAccessed September 25, 2015
- European Medicines AgencyEuropean Medicines Agency gives new advice to better manage risk of adverse effects on the heart with Gilenya Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Press_release/2012/04/WC500125690.pdfAccessed November 11, 2015
- RaccaVDi RienzoMCavarrettaRFingolimod effects on left ventricular function in multiple sclerosisMult Scler Epub201563
- KillesteinJVennegoorAvan GoldeAEBourezRLWijlensMLWattjesMPPML-IRIS during fingolimod diagnosed after natalizumab discontinuationCase Rep Neurol Med2014201430787225506447
- CalicZCappelen-SmithCHodgkinsonSJMcDougallACuganesanRBrewBJTreatment of progressive multifocal leukoencephalopathy-immune reconstitution inflammatory syndrome with intravenous immunoglobulin in a patient with multiple sclerosis treated with fingolimod after discontinuation of natalizumabJ Clin Neurosci201522359860025523125
- US Food Drug AdministrationFDA Drug Safety Communication: FDA warns about cases of rare brain infection with MS drug Gilenya (fingolimod) in two patients with no prior exposure to immunosuppressant drugs Available from: http://www.fda.gov/Drugs/DrugSafety/ucm456919.htmAccessed September 25, 2015
- BergerJRAksamitAJCliffordDBPML diagnostic criteria: consensus statement from the AAN Neuroinfectious Disease SectionNeurology201380151430143823568998
- TylerKLFingolimod and risk of varicella-zoster virus infection: back to the future with an old infection and a new drugJAMA Neurol2015721101325420159
- PfenderNJelcicILinnebankMSchwarzUMartinRReactivation of herpesvirus under fingolimod: a case of severe herpes simplex encephalitisNeurology201584232377237825957334
- IssaNPHentatiAVZV encephalitis that developed in an immunized patient during fingolimod therapyNeurology20158419910025416038
- LindåHvon HeijneAA case of posterior reversible encephalopathy syndrome associated with Gilenya® (fingolimod) treatment for multiple sclerosisFront Neurol201563925788891
- AchtnichtsLObrejaOConenAFuxCANedeltchevKCryptococcal meningoencephalitis in a patient with multiple sclerosis treated with fingolimodJAMA Neurol201572101203120526457631
- HuangDDisseminated cryptococcosis in a patient with multiple sclerosis treated with fingolimodNeurology201585111001100326291283
- TullyTBarkleyASilberEKaposi sarcoma in a patient with relapsing-remitting multiple sclerosis receiving fingolimodNeurology201584191999200125878178
- PilzGHarrerAWipflerPTumefactive MS lesions under fingolimod: a case report and literature reviewNeurology201381191654165824097813
- HellmannMALevNLotanITumefactive demyelination and a malignant course in an MS patient during and following fingolimod therapyJ Neurol Sci20143441–219319725001515
- HarirchianMHTaalimiASiroosBEmerging tumefactive MS after switching therapy from interferon-beta to fingolimod: a case reportMult Scler Relat Disord20154540040226346786
- LysandropoulosAPBenghiatFSevere auto-immune hemolytic anemia in a fingolimod-treated multiple sclerosis patientMult Scler201319111551155223817558
- van RossumJALooysenEEDanielsJMKillesteinJFingolimod-induced asthma deterioration in a patient with relapsing-remitting multiple sclerosisMult Scler201420131792179324866203
- AlroughaniRFingolimod-associated amenorrhea: a report of three casesMult Scler201420121662166424515730
- RussoMGuarneriCMazzonESessaEBramantiPCalabròRSFingolimod-associated peripheral vascular adverse effectsMayo Clin Proc201590101424142726349949
- MaseraSChiavazzaCMattiodaAOccurrence of ecchymotic angioedema-like cutaneous lesions as a possible side effect of fingolimodMult Scler201420121666166724603883
- KraemerMWeberRHeroldMBerlitPReversible cerebral vasoconstriction syndrome associated with fingolimod treatment in relapsing-remitting multiple sclerosis three months after childbirthMult Scler201521111473147526283695
- SamaraweeraAPCohenSNAkayEMEvangelouNLymphomatoid papulosis: a cutaneous lymphoproliferative disorder in a patient on fingolimod for multiple sclerosisMult Scler Epub2015728
- AbreuPPeixotoCCarvalhoCSantosLSarmentoASáMJA case of hemophagocytic lymphohistiocytosis syndrome in a patient with multiple sclerosis on fingolimod therapy [abstract]Neurology201482Suppl 10P2.206
- European Medicines AgencyGilenya: procedural steps taken and scientific information after the authorisation Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Procedural_steps_taken_and_scientific_information_after_authorisation/human/002202/WC500111236.pdfAccessed September 25, 2015
- KarlssonGFrancisGKorenGPregnancy outcomes in the clinical development program of fingolimod in multiple sclerosisNeurology201482867468024463630
- JonesBMultiple sclerosis: study reinforces need for contraception in women taking fingolimodNat Rev Neurol201410312524514867
- HershCMHara-CleaverCRudickRACohenJABermelRAOntanedaDExperience with fingolimod in clinical practiceInt J Neurosci2015125967868525271798
- FoxEEdwardsKBurchGOutcomes of switching directly to oral fingolimod from injectable therapies: results of the randomized, open-label, multicenter, Evaluate Patient OutComes (EPOC) study in relapsing multiple sclerosisMult Scler Relat Disord20143560761926265273
- SormaniMPArnoldDLDe StefanoNTreatment effect on brain atrophy correlates with treatment effect on disability in multiple sclerosisAnn Neurol2014751434924006277
- CalabreseMGajofattoABenedettiMDTherapeutic strategies for relapsing-remitting multiple sclerosis: a special focus on reduction of grey matter damage as measured by brain atrophyExpert Rev Neurother201414121417142825391525
- FilippiniGDel GiovaneCVacchiLImmunomodulators and immunosuppressants for multiple sclerosis: a network meta-analysisCochrane Database Syst Rev20136CD00893323744561
- GajofattoABenedettiMDTreatment strategies for multiple sclerosis: when to start, when to change, when to stop?World J Clin Cases20153754555526244148
- TramacereIDel GiovaneCSalantiGD’AmicoRFilippiniGImmunomodulators and immunosuppressants for relapsing-remitting multiple sclerosis: a network meta-analysisCochrane Database Syst Rev20159CD01138126384035
- PapadopoulosMCBennettJLVerkmanASTreatment of neuromyelitis optica: state-of-the-art and emerging therapiesNat Rev Neurol201410949350625112508
- European Medicines AgencyGilenya Available from: http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/002202/human_med_001433.jsp&mid=WC0b01ac058001d124Accessed November 11, 2015